Are there any concerns with the use of IL-23 or IL-17 inhibitors in patients with a history of cutaneous squamous cell carcinoma (cSCC)?

Featuring April Armstrong, MD, MPH | Co-Director | Professor and Chief, Division of Dermatology, University of California Los Angeles (UCLA), Los Angeles, CA, USA | Published October 19, 2021